Advertisement

Topics

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

09:00 EDT 24 Sep 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license fr...

Other Sources for this Article

GeneCentric Therapeutics, Inc.
Walter M. Capone, 984-329-3837
Chief Business Officer
walter.capone@GeneCentric.com

NEXT ARTICLE

More From BioPortfolio on "GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pancreatic Cancer
The pancreas secretes a number of important hormones into the digestive tract and the blood stream. Cancers are most commonly exocrine than endocrine (neuroendocrine) tumors. Functional tumors secrete hormones; Insulinoma, Gastrinoma, Somatostatinoma, VI...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...